Research On Tamoxifen Leads To Recommendation For CYP2D6 Gene Test
Findings from a new study have prompted Mayo Clinic researchers to recommend CYP2D6 gene testing for postmenopausal women about to begin tamoxifen therapy. This data confirms that women with an inherited deficiency in the CYP2D6 gene, which is important for the metabolism of tamoxifen, have a nearly fourfold higher risk of early breast cancer recurrence compared to women who have not inherited the deficiency.
More: continued here
Filed under: Breast Cancer on December 19th, 2008